heat shock protein family A (Hsp70) member pseudogene 19Genealiases: []
Q-omics provides the consensus-scored HSPA8P19 profile across patient tissues and cancer cell-line models. HSPA8P19 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, HSPA8P19 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, HSPA8P19 RNA expression shows 9,870 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight CHOL, KIRC, and HNSC as cancer lineages where HSPA8P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA8P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA8P19 survival associations across molecular data types. HSPA8P19 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA8P19 RNA expression–survival associations across cancer types. High HSPA8P19 expression shows unfavorable associations in CHOL, LUSC, THYM and PCPG, but favorable associations in ACC and LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for HSPA8P19 RNA expression.
This table summarizes HSPA8P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSPA8P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA8P19 shows higher tumor expression in KIRC, LUSC, BRCA, HNSC and LIHC. The KIRC box plot shows higher HSPA8P19 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p < 0.001).
This table shows molecular features associated with HSPA8P19 in patient tissues and cancer cell lines. In patient samples, HSPA8P19 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
